Validation of the interleukin-10 knockout mouse model of colitis: Antitumour necrosis factor-antibodies suppress the progression of colitis

Clinical and Experimental Immunology

Volumn 133, Issue 1, 2003, Pages 38-43

  Scheinin, Tom ^a,d   Butler, D M ^b   Salway, F ^b   Scallon, B ^c   Feldmann, M ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CENTOCOR INC   (United States)

^d Surgical Hospital   (Finland)

Author keywords

Anti TNF antibodies; Clinical score; IBD; Interleukin 10; Knockout mice

Indexed keywords

CYTOKINE; INFLIXIMAB; INTERLEUKIN 10; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; EXPERIMENTAL MODEL; FECES ANALYSIS; HISTOPATHOLOGY; IMMUNOTHERAPY; INFLAMMATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM; VALIDATION PROCESS;

ANIMALS; ANTIBODIES; COLITIS; CROHN DISEASE; CYTOKINES; FECES; IMMUNIZATION, PASSIVE; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-10; INTESTINES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, ANIMAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038723693     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02193.x     Document Type: Article

References (35)

1. Crohn B, Ginzburg L, Oppenheimer G. Regional ileitis, a pathological and clinical entity. J Am Med Assoc 1932; 99:1323-9.
2. Niv Y, Abuksis G, Fraser GM. Epidemiology of Crohn's disease in Israel: a survey of Israeli kibbutz settlements. Am J Gastroenterol 1999; 94:2961-5.
3. Danze PM, Colombel JF, Jacquot S et al. Association of HLA class II genes with susceptibility to Crohn's disease. Gut 1996; 39:69-72.
4. Cariappa A, Sands B, Forcione D et al. Analysis of MHC class II DP, DQ and DR alleles in Crohn's disease. Gut 1998; 43:210-5.
5. Yang H, Plevy SE, Taylor K et al. Linkage of Crohn's disease to the major histocompatibility complex region is detected by multiple non-parametric analyses. Gut 1999; 44:519-26.
6. Trachtenberg EA, Yang H, Hayes E et al. HLA class II haplotype associations with inflammatory bowel disease in Jewish (Ashkenazi) and non-Jewish caucasian populations. Hum Immunol 2000; 61:326-33.
7. Brynskov J, Tvede N. Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease. Gut 1990; 31:795-9.
8. Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg 1998; 22:382-9.
9. Tagore A, Gonsalkorale WM, Pravica V et al. Interleukin-10 (IL-10) genotypes in inflammatory bowel disease. Tissue Antigens 1999; 54:386-90.
10. MacDonald TT. Inflammatory bowel disease in knockout mice. Current Biol 1994; 4:261-3.
11. Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation ant their relation to human inflammatory bowel disease. Curr Op Immunol 1999; 11:648-56.
12. Leach MW, Bean AGD, Mauze S et al. Inflammatory bowel disease in C.B-17 scid mice reconstituted with the CD45RBhigh subset of CD4+ T cells. Am J Pathol 1996; 148:1503-5.
13. Rennick DM, Fort MM, Davidson NJ. Studies with IL-10 -/- mice: an overview. J Leukoc Biol 1997; 61:389-96.
14. Braegger CP, Nicholls S, Murch SH et al. Tumor necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339:89-91.
15. Lukacs NW, Chensue SW, Strieter R et al. Inflammatory granuloma formation is mediated by TNF-alpha inducible intercellular adhesion molecule-1. J Immunol 1994; 152:5883-9.
16. Elliott MJ, Maini RN, Feldmann M et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNFα. Arthritis Rheum 1993; 36:1681-90.
17. van Dullemen HM, van Deventer SJH, Hommes DW et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109:129-35.
18. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029-35.
19. Present DH, Rutgeeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398-405.
20. van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 1997; 113:383-9.
21. Sands BE, Bank S, Sninsky CA et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 1999; 117:58-64.
22. Powrie F, Leach MW, Mauze S et al. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhigh CD4+ T cells. Immunity 1994; 1:553-62.
23. Rennick D, Davidson N, Berg D. Interleukin-10 gene knock-out mice. a model of chronic inflammation. Clin Immunol Immunopathol 1995; 76:174-8.
24. Saiki T, Mitsuyama K, Toyonaga A et al. Detection of pro- and anti-inflammatory cytokines in stools of patients with IBD. Scand J Gastroenterol 1998; 33:616-22.
25. Butler DM, Malfait A-M, Maini RN et al. Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. Eur J Immunol 1999; 29:2205-12.
26. Winship DH, Summers RW, Singleton JW et al. National cooperative Crohn's disease study. study design and conduct of the study. Gastroenterology 1979; 77:829-42.
27. Raqib R, Lindberg AA, Björk L et al. Down-regulation of gamma interferon, tumor necrosis factor type I, interleukin 1 (IL-1) type I, IL-3, IL-4, and transforming growth factor β type I receptors at the local site during the acute phase of shigella infection. Infect Immun 1995; 63:3079-87.
28. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad U S A 1992; 89:9784-8.
29. Berg DJ, Davidson N, Kühn R et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4+ TH1-like responses. J Clin Invest 1996; 98:1010-20.
30. Feldmann M, Elliott MJ, Woody JN et al. Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol 1997; 64:283-350.
31. van Deventer SJH. Immunotherapy of Crohn's disease. Scand J Immunol 2000; 51:18-22.
32. Rutgeerts P, D'Haens G, Targan S et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (Infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117:761-9.
33. Williams RO, Mason LJ, Feldmann M et al. Synergy between anti-CD4 and antiTNF in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994; 91:2762-6.
34. Rankin EC, Choy EHS, Kassimos D et al. A double blind, placebo-controlled, ascending dose trial of the recombinant humanised anti-TNFα antibody CDP571 in patients with rheumatoid arthritis (RA): a preliminary report. Arth Rheum 1994; 37:S295.
35. Chiller JM, HabichtGS, Weigle WO. Cellular sites of immunologic unresponsiveness. Proc Natl Acad Sci USA 1970; 65:551-6.